Reviva Pharmaceuticals Holdings, Inc. (RVPH)

US — Healthcare Sector
Peers:   OCUP  PLX  EYPT  SLS  INAB  CUE  LTRN  GRCL  SGTX  ZVSA  KRBP  UNCY  ATHA  FBIO  ACAD  CABA 

Automate Your Wheel Strategy on RVPH

With Tiblio's Option Bot, you can configure your own wheel strategy including RVPH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol RVPH
  • Rev/Share 0.0
  • Book/Share 0.0245
  • PB 27.4946
  • Debt/Equity 0.5638
  • CurrentRatio 1.0056
  • ROIC -22.6654

 

  • MktCap 31502760.0
  • FreeCF/Share -1.012
  • PFCF -0.9391
  • PE -0.7467
  • Debt/Assets 0.0296
  • DivYield 0
  • ROE 7.2282

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
RVPH
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral

CUPERTINO, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, taking place June 16-17, 2025.

Read More
image for news Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
RVPH
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral

– Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms – – Generally well-tolerated with low rates of adverse events and discontinuation – – Brilaroxazine improved multiple neuroinflammatory markers reported to enhance efficacy and mitigate side effects – – Virtual investor webcast today at 8:00 a.m. EDT – CUPERTINO, Calif.

Read More
image for news Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

About Reviva Pharmaceuticals Holdings, Inc. (RVPH)

  • IPO Date 2018-10-18
  • Website https://revivapharma.com
  • Industry Biotechnology
  • CEO Dr. Laxminarayan Bhat Ph.D.
  • Employees 14
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.